PMS AND PMDD
Carlini SV, Lanza di Scalea T, McNally ST, Lester J, Deligiannidis KM. Int J Womens Health. 2022 Dec 21;14:1783-1801. Free article.
Clinical correlates of women endorsing premenstrual suicidal ideation: a cross-sectional study.
Carlini SV, Weiss SJ, Mordukhaev L, Jacob S, Flynn HA, Deligiannidis KM. Biopsychosoc Med. 2022 Nov 8;16(1):23.
In this group of women reporting premenstrual symptoms, nearly a third of women reported new or worsening premenstrual passive or active SI. Women who reported PMSI were significantly more likely to be single, unemployed, and childless as well as significantly more likely to report interference from premenstrual symptoms, histories of psychiatric hospitalization, adverse childhood events, suicide attempts, and current and past depression and anxiety compared to women without PMSI.
INFERTILITY AND MENTAL HEALTH
PSYCHIATRIC ILLNESS DURING PREGNANCY
Arditi-Arbel B, Hamdan S, Winterman M, Gvion Y. Front Psychiatry. 2023 Jan 19;13:987673.
In this systematic review, sleep disturbance, psychopathology, and social support have been identified as dominant risk factors for suicidal behavior among pregnant and postpartum women, as well as medical conditions and aversive life events.
MEDICATIONS AND PREGNANCY
Hutchison SM, Brain U, Grunau RE, Kuzeljevic B, Irvine M, Mâsse LC, Oberlander TF. BJPsych Open. 2023 Feb 1;9(2):e26.
Maternal depressed mood at the third trimester assessment, not prenatal SSRI exposure, was associated with longitudinal patterns of higher levels of internalizing and anxiety behaviors across childhood from 3 to 12 years of age.
POSTPARTUM PSYCHIATRIC ILLNESS
Krishnamurti T, Allen K, Hayani L, Rodriguez S, Davis AL. Procedia Comput Sci. 2022;206:132-140.
Natural language from open-ended writing prompts in a prenatal care mobile health app and self-reported daily mood, were entered by patients using the tool. Open-ended text within a 30-day and 60-day timeframe of completing an EPDS was found to be moderately predictive of moderate to severe depression risk (AUROC=0.66 and 0.67, for each respective timeframe). When combined with average daily reported mood, open-ended text showed good predictive power (AUROC=0.87).
A pilot randomized controlled trial of a lay telephone coaching and web-based intervention for postpartum depression and anxiety: The MPOWER study.
Schwartz H, McCusker J, Da Costa D, Singh S, Baskaran S, Belzile E, Van Roost K.
Internet Interv. 2022 Dec 23;31:100597.
The estimates of the effect of the intervention on mental health outcomes at 6-months were imprecise but point estimates and confidence intervals were consistent with a moderate beneficial effect of the intervention on both symptoms of depression and anxiety (fully adjusted effects sizes: 0.51 (95 % CI: [-0.14, 1.17]) and 0.56 (95 % CI: [-0.09, 1.22]), respectively).
Relationship between antenatal sleep quality and depression in perinatal women: A comprehensive meta-analysis of observational studies.
Fu T, Wang C, Yan J, Zeng Q, Ma C. J Affect Disord. 2023 Feb 3;327:38-45.
In this meta-analysis, women who experienced poor sleep quality during pregnancy were at a significantly higher risk of developing antenatal depression (3.72 times higher) and postpartum depression (2.71 times higher).
Association between sleep disorders during pregnancy and risk of postpartum depression: a systematic review and meta-analysis.
Li H, Li H, Zhong J, Wu Q, Shen L, Tao Z, Zhang H, Song S. Arch Womens Ment Health. 2023 Feb 4.
Meta-analysis indicated that sleep disorders during pregnancy resulted in a statistically significant increased risk of PPD (OR: 2.36 95% CI: 1.72, 2.32).
Effect of Zuranolone on Concurrent Anxiety and Insomnia Symptoms in Women With Postpartum Depression.
Deligiannidis KM, Citrome L, Huang MY, Acaster S, Fridman M, Bonthapally V, Lasser R, Kanes SJ. J Clin Psychiatry. 2023 Jan 30;84(1):22m14475.
Zuranolone was associated with concurrent improvements in depressive and anxiety symptoms, with beneficial effects on insomnia symptoms and patient-perceived functional health in adults with PPD.
MEDICATIONS AND BREASTFEEDING
PERINATAL SUBSTANCE USE
MATERNAL MENTAL HEALTH AND CHILD OUTCOMES
Brooker RJ, Mistry-Patel S, Kiel EJ, Liu S, Van Lieshout RJ, Schmidt LA, John-Henderson N. J Affect Disord Rep. 2023 Jan;11:100481.
gh. Negative reactivity, assessed via maternal report of infant behavior, was related to smaller postnatal declines in maternal anxiety, while infant negative reactivity, at the level of neuroendocrine function, was largely unrelated to longitudinal changes in maternal anxiety symptoms.
Association of Maternal Depression During Pregnancy and Recent Stress With Brain Age Among Adult Offspring.
Mareckova K, Marecek R, Jani M, Zackova L, Andryskova L, Brazdil M, Nikolova YS.
JAMA Netw Open. 2023 Jan 3;6(1):e2254581.
Prenatal exposure to maternal depression and recent stress may have independent associations with brain age and the pace of aging, respectively, in young adulthood.
Effects of maternal childhood trauma on child emotional health: maternal mental health and frontoamygdala pathways.
Uy JP, Tan AP, Broeckman BBFP, Gluckman PD, Chong YS, Chen H, Fortier MV, Meaney MJ, Callaghan BL. J Child Psychol Psychiatry. 2023 Mar;64(3):426-436.
Data from this study supports the existence of intergenerational influences of parental exposure to childhood trauma on childhood risk for psychopathology in the next generation and point to the importance of maternal factors proximal to the second generation (maternal prenatal and postpartum mental health) in determining the intergenerational impact of maternal early experiences.
Prospective associations between various prenatal exposures to maternal psychological stress and neurodevelopment in children within 24 months after birth.
Wei Q, Zou J, Ma X, Xiao X, Zhang Y, Shi H. J Affect Disord. 2023 Feb 3;327:101-110.
Maternal perceived stress and negative life-event stress around the time of conception, and anxiety and depressive symptoms during late pregnancy were negatively associated with scores of children’s neurodevelopment at two, six, 12, and 24 months of age; while maternal life-event experiences were positively associated with scores of children’s neurodevelopment.
MENOPAUSE AND MENTAL HEALTH
Simon JA, Anderson RA, Ballantyne E, Bolognese J, Caetano C, Joffe H, Kerr M, Panay N, Seitz C, Seymore S, Trower M, Zuurman L, Pawsey S. Menopause. 2023 Jan 31.
Elinzanetant (NT-814), a selective NK-1,3 receptor antagonist, is an effective and well-tolerated nonhormone treatment option for postmenopausal women with VMS and associated sleep disturbance.
OTHER TOPICS IN WOMEN’S MENTAL HEALTH